Literature DB >> 8101665

Alpha 2-adrenergic blockade prevents hyperglycemia and hepatic glutathione depletion in nickel-injected rats.

C Alvarez1, C Bladé, J Cartañà.   

Abstract

To study the involvement of the adrenergic system in nickel-induced hyperglycemia and hepatic glutathione depletion in rats, several adrenergic antagonists (phentolamine, prazosin, yohimbine, and propranolol) were administered in a single ip injection before acute nickel treatment (ip injection). Moreover, the effects of nickel on adrenalectomized rats were investigated. Hyperglycemia was suppressed by either alpha-antagonist phentolamine or alpha 2-antagonist yohimbine. Such blockade coincided with the prevention of the hypoinsulinemic response to nickel, which occurred simultaneously to hyperglycemia. Nickel-induced hyperglucagonemia remained almost unaltered by pretreatment with adrenergic antagonists. In adrenalectomized animals treated with nickel, hyperglycemia was attenuated, whereas hypoinsulinemia still persisted. Therefore, catecholamines seemed to participate in nickel-induced hyperglycemia, directly, i.e., stimulating glucose output from liver, or by modulating insulin secretion throughout alpha 2-adrenoreceptor stimulation in pancreatic islets. Hepatic glutathione depletion caused by nickel was prevented by either alpha 1-antagonist prazosin or alpha 2-antagonist yohimbine. Interestingly, adrenalectomy did not alter the drop in hepatic GSH induced by nickel treatment. Overall results suggest that the effects observed after acute nickel exposure were caused by a combined action of catecholamines released from the adrenal glands and those released at the efferent nerves. Such events have been found to be mediated by alpha 2-adrenergic receptors.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8101665     DOI: 10.1006/taap.1993.1135

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  1 in total

1.  Environmental Nickel Exposure and Diabetes in a Nationally Representative Sample of US Adults.

Authors:  Tyler J Titcomb; Buyun Liu; Hans-Joachim Lehmler; Linda G Snetselaar; Wei Bao
Journal:  Expo Health       Date:  2021-09-29       Impact factor: 8.835

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.